<DOC>
	<DOC>NCT01436838</DOC>
	<brief_summary>Non-adherence reduces treatment benefit and can bias the assessment of treatment efficacy thereby involving safety risks for the patient and influencing health cost-effectiveness. This observational study will concentrate upon the role of MS nurses in influencing adherence. This study will examine the influence of initial and subsequent periodic nurse interviews which aim to improve adherence to BetaferonÂ® treatment.</brief_summary>
	<brief_title>China Betaferon Adherence, Coping and Nurse Support Study</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Relapsingremitting multiple scelrosis (RRMS) and secondary progressive multiple sclerosis (SPMS) patients Having Betaferon treatment, including patients who are First time using; or Restaring; or Switching from other diseases modifying drugs (DMDs) Known or newly identified contraindication for administration of Betaferon according to Summary of Product Characteristic (SmPC).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Relapsing-Remitting Multiple Sclerosis</keyword>
	<keyword>Secondary Progressive Multiple Sclerosis</keyword>
</DOC>